Ann: Emyria Gets $2M Bids, Sets $3.1M Entitlement Offer, page-38

I think its the wrong thing to focus on, IHL gets more of a pump-and-dump on usa listings and far far more focus on it than its actual clinical pipeline. (do some trend analysis) and it's about 90% focused on listing very little focus on the actual clinical pipeline. - you can see them trying to rinse and repeat the same playbook again at the moment.... it worked once.

get a TGA-approved product, the largest RWD set in cannabis and spin up MDMA and ketamine RWD capture, leverage it and move to FDA approval, value will come.

There is a reason that EMD is the leader here and have Jazz phama (who own the only FDA-approved 7B asset) keeping a close eye on emd, you dont see this with IHL for example and lots of bag holders. they have mostly retail holding their bags now as most of their directors etc have jumped out on the last pump to 1B - yet they currently lost most of that.

EMD is a little different, its still a sightly held register (IHL 65% retial vs EMDs 44%) mostly with the top 20 and a much smaller retail holding. They are far more prudent with their money management, costs, and director payments. (e.g. IHLs CEO gets paid $1.5M while Winlow gets paid only 30% of that at 0.5M). Far more alignment to success here with insiders holding a large amound (IHL insiders 14% - vs EMD 43%) - none of their insiders have bought within the last 12 months, while EMD has.

From a CR point of view, EMD RWD and clinics actually run themself - in profit/break even. We only need capital on the drug developer/growth side. - capital raised for specific goals, and then to wait for results. - at any time these can be paused, and the company continues to run happy day (largely).